At ImmunoNanoMed, we are transforming the way infectious diseases are fought with our groundbreaking, scalable production of particle-based vaccines (PBVs) for influenza and other infectious diseases. Our patented technology offers significant advancements over current vaccine approaches, promising more effective and durable immunity.

Faster, More Efficient Vaccine Manufacturing

Traditional flu vaccines rely on egg-based production methods, which are time-consuming and resource-intensive. ImmunoNanoMed’s use of recombinant antigens in the PBV synthesis process enables shorter production times, addressing one of the major challenges in current vaccine manufacturing. Our innovative method ensures that vaccines are produced more quickly and efficiently, allowing for faster responses to emerging viral threats.

Key Innovations: Inhalable, Room-Temperature-Stable Vaccines

Our most significant breakthrough lies in the development of an inhalable, room-temperature-stable flu vaccine using polyanhydride particles. This dry powder formulation provides sustained antigen delivery, resulting in long-lasting immunity. By including surface antigens (hemagglutinin), conserved antigens (nucleoprotein), and a small molecule adjuvant (CpG oligonucleotide), our PBVs induce both strong antibody and T cell responses, ensuring protection against a wide range of influenza variants.

Targeting Immunological Niches for Superior Immunity

Our PBV technology is designed to specifically target immune niches in the lungs, key for enhancing both cellular and humoral immunity. This is crucial for inducing and maintaining lung-resident T and B cells, which are vital for long-term protection. Unlike traditional vaccines that fail to trigger lung-resident T cell responses, PBVs induce memory T cells that provide cross-strain protection, providing broader immunity against viral variants.

We are committed to advancing our technology toward clinical testing, with a focus on quality, scalability, and broad protection. Stay tuned as we move closer to a future where flu vaccines are more reliable and accessible to all.